2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for detailed information. †ACCF/AHA Representative. ‡ACCF/AHA Task Force on Performance Measures Liaison. §Society of Thoracic Surgeons Representative. ʈAmerican Association for Thoracic Surgery Representative. ¶Heart Rhythm Society Representative. #Society for Cardiovascular Angiography and Interventions Representative. guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. by selecting either the " By Topic " link or the " By Publication Date " link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com. Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development, visit http://my.americanheart.org/statements and select the " Policies and Development " link.

[1]  B. Maron.  Hypertrophic cardiomyopathy centers. , 2009, The American journal of cardiology.

[2]  R. Bonow,et al.  Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. , 1983, The American journal of cardiology.

[3]  J. Criley.  Unobstructed thinking (and terminology) is called for in the understanding and management of hypertrophic cardiomyopathy. , 1997, Journal of the American College of Cardiology.

[4]  N. Smedira,et al.  Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. , 2004, The American journal of cardiology.

[5]  E. V. Vaughan Williams,et al.  Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods. , 1977, British heart journal.

[6]  N. Smedira,et al.  Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. , 2002, Journal of the American College of Cardiology.

[7]  S. Nakatani,et al.  Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. , 1995, Journal of the American College of Cardiology.

[8]  S. Solomon,et al.  Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. , 1994, The Journal of clinical investigation.

[9]  J. Gottdiener,et al.  Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. , 1981, The American journal of cardiology.

[10]  M. Sherrid,et al.  Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction. , 2003, The Annals of thoracic surgery.

[11]  N. Smedira,et al.  Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[12]  R. Gramiak,et al.  Long-term propranolol therapy in muscular subaortic stenosis. , 1970, British heart journal.

[13]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[14]  B. Maron.  Sudden death in young athletes. , 1980, The New England journal of medicine.

[15]  J. Ross,et al.  Effects of Beta Adrenergic Blockade on the Circulation, with Particular Reference to Observations in Patients with Hypertrophic Subaortic Stenosis , 1964, Circulation.

[16]  B. Maron,et al.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. , 1979, Circulation.

[17]  M. Sherrid,et al.  Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. , 1998, Circulation.

[18]  S. Ommen,et al.  Left Ventricular Outflow Tract Gradient Variability in Hypertrophic Cardiomyopathy , 2009, Clinical cardiology.

[19]  L. Fananapazir,et al.  Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. , 2000, Journal of the American College of Cardiology.

[20]  B. Gersh,et al.  Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. , 2009, Journal of the American College of Cardiology.

[21]  W. Williams,et al.  Surgical intervention and support for cardiomyopathies of childhood , 1992 .

[22]  P. Elliott,et al.  Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[23]  L. Cohn,et al.  Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. , 1992, The American journal of cardiology.

[24]  A. L'Abbate,et al.  Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. , 1991, Journal of the American College of Cardiology.

[25]  C. Lambrew,et al.  Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients , 1964, Circulation.

[26]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. , 1999, JAMA.

[27]  H. Watkins,et al.  Sudden death due to troponin T mutations. , 1997, Journal of the American College of Cardiology.

[28]  L. Harris,et al.  Side Effects of Long-term Amiodarone Therapy , 1983, Circulation.

[29]  R. Siegel,et al.  Has 'obstruction' hindered our understanding of hypertrophic cardiomyopathy? , 1985, Circulation.

[30]  E. Sonnenblick,et al.  Studies on Digitalis: XV. Effects of Cardiac Glycosides on Myocardial Force‐Velocity Relations in the Nonfailing Human Heart , 1966, Circulation.

[31]  M. Russo,et al.  Prevalence of Fabry Disease in Female Patients With Late-Onset Hypertrophic Cardiomyopathy , 2004, Circulation.

[32]  Michael J Ackerman,et al.  Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. , 2004, Circulation.

[33]  J. Seidman,et al.  Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. , 2009, JAMA.

[34]  R. Desnick,et al.  High incidence of later-onset fabry disease revealed by newborn screening. , 2006, American journal of human genetics.

[35]  Mario J. Garcia,et al.  Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy , 2007, Heart.

[36]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[37]  E. Wigle,et al.  MUSCULAR SUBAORTIC STENOSIS; THE INTERRELATION OF WALL TENSION, OUTFLOW TRACT "DISTENDING PRESSURE" AND ORIFICE RADIUS. , 1965, The American journal of cardiology.

[38]  B. Maron,et al.  Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. , 1995, Journal of the American College of Cardiology.

[39]  R. Whalen,et al.  Demonstration of the dynamic nature of idiopathic hypertrophic subaortic stenosis. , 1963, The American journal of cardiology.

[40]  W. Mckenna,et al.  Management of hypertrophic cardiomyopathy. , 1993 .

[41]  Iacopo Olivotto,et al.  Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[42]  Udo Sechtem,et al.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. , 2010, Journal of the American College of Cardiology.

[43]  B. Maron,et al.  Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2009, Circulation.

[44]  P. Grayburn,et al.  Spontaneous Variability of Left Ventricular Outflow Tract Gradient in Hypertrophic Obstructive Cardiomyopathy , 1998, Circulation.

[45]  P. Lambiase,et al.  Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. , 2009, European heart journal.

[46]  A. Tajik,et al.  Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. , 1997, Journal of the American College of Cardiology.

[47]  H. Kuhn,et al.  Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients , 2004, Heart.

[48]  Michael J Ackerman,et al.  Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. , 2010, Journal of the American College of Cardiology.

[49]  G. Boriani,et al.  Prevention of Sudden Death in Hypertrophic Cardiomyopathy: But Which Defibrillator for Which Patient? , 2004, Circulation.

[50]  A. Abdulla,et al.  Long-term medical management of hypertrophic obstructive cardiomyopathy. , 1978, The American journal of cardiology.

[51]  F. Ellis,et al.  Surgical Relief of Diffuse Subvalvular Aortic Stenosis , 1961, Circulation.

[52]  R. Hui,et al.  Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. , 2004, The American journal of medicine.

[53]  W. Mckenna,et al.  Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. , 1984, The American journal of cardiology.

[54]  B. Maron,et al.  Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population , 1998, Heart.

[55]  R. Bonow,et al.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. , 1981, The American journal of cardiology.

[56]  D. Pennell,et al.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.

[57]  S. Ommen,et al.  Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[58]  S. Reith,et al.  Surgical correction of hypertrophic obstructive cardiomyopathy with combined myectomy, mobilisation and partial excision of the papillary muscles. , 1994, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[59]  D. Rowbotham,et al.  Potentially dangerous effect of disopyramide on atrioventricular conduction in a patient on digitalis. , 1980, British medical journal.

[60]  B. Maron,et al.  Implantable Defibrillators and Prevention of Sudden Death in Hypertrophic Cardiomyopathy , 2008, Journal of cardiovascular electrophysiology.

[61]  M. Link,et al.  Utility of cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease. , 2009, Circulation.

[62]  M. Gold,et al.  Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[63]  F. Girolami,et al.  Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[64]  W. Chung,et al.  Short Communication: The Cardiac Myosin Binding Protein C Arg502Trp Mutation: A Common Cause of Hypertrophic Cardiomyopathy , 2010, Circulation research.

[65]  R. Swanton,et al.  Hemodynamic studies of beta blockade in hypertrophic obstructive cardiomyopathy. , 1977, European journal of cardiology.

[66]  D. Callans.  Ablation of Atrial Fibrillation in the Setting of Hypertrophic Cardiomyopathy , 2008, Journal of cardiovascular electrophysiology.

[67]  K. Schenck-Gustafsson,et al.  Comparative class 1 electrophysiologic and anticholinergic effects of disopyramide and its main metabolite (mono-N-dealkylated disopyramide) in healthy humans , 1992, Cardiovascular Drugs and Therapy.

[68]  B. Maron.  Hypertrophic cardiomyopathy: an important global disease. , 2004, The American journal of medicine.

[69]  Barry J Maron,et al.  Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. , 2010, The American journal of cardiology.

[70]  Warren J Manning,et al.  Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy , 2008, Circulation. Heart failure.

[71]  Barry J Maron,et al.  Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[72]  E. D. Wigle,et al.  Expert consensus document American College of Cardiology / European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy , 2003 .

[73]  P. Boekstegers,et al.  Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society. , 2005, Zeitschrift fur Kardiologie.

[74]  E. Braunwald,et al.  Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta‐Adrenergic Blockade , 1967, Circulation.

[75]  W. Hop,et al.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.

[76]  Robert G. Hauser,et al.  Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator , 2005, Circulation.

[77]  B. Kimball,et al.  Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. , 1988, The American journal of cardiology.

[78]  M. Z. Berisso,et al.  Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. , 1989, The New England journal of medicine.

[79]  W. Morrow,et al.  Cardiomyopathy and heart transplantation in children , 2000, Current opinion in cardiology.

[80]  E. Braunwald,et al.  The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[81]  B. Kimball,et al.  Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy. , 1993, American heart journal.

[82]  B. Maron,et al.  Implications of left ventricular remodeling in hypertrophic cardiomyopathy. , 1998, The American journal of cardiology.

[83]  W. Williams,et al.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.

[84]  G. Boriani,et al.  Heart transplantation in hypertrophic cardiomyopathy. , 2008, American Journal of Cardiology.

[85]  J. Seidman,et al.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling , 2005, Journal of Medical Genetics.

[86]  Rachael,et al.  Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. , 2008, Mayo Clinic proceedings.

[87]  J. K. Dunn,et al.  Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. , 2000, Journal of the American College of Cardiology.

[88]  W. Williams,et al.  Results of surgery for hypertrophic obstructive cardiomyopathy. , 1987, Circulation.

[89]  S. Nagueh,et al.  Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. , 2008, JACC. Cardiovascular interventions.

[90]  K. McDonald,et al.  Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. , 1988, European heart journal.

[91]  A. Marian,et al.  Molecular Genetic Basis of Hypertrophic Cardiomyopathy: , 1998, Journal of cardiovascular electrophysiology.

[92]  K. Smith,et al.  Depression, anxiety, and quality of life in patients with obstructive hypertrophic cardiomyopathy three months after alcohol septal ablation. , 2007, The American journal of cardiology.

[93]  S. Bernasconi,et al.  Update on age at menarche in Italy: toward the leveling off of the secular trend. , 2010, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[94]  W. Manning,et al.  Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.

[95]  J. Seidman,et al.  Homozygous Mutation in Cardiac Troponin T: Implications for Hypertrophic Cardiomyopathy , 2000, Circulation.

[96]  Michael Jerosch-Herold,et al.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy , 2005, Circulation.

[97]  B. Maron,et al.  Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy , 2009 .

[98]  K. McBride,et al.  Parental Knowledge and Attitudes Toward Hypertrophic Cardiomyopathy Genetic Testing , 2010, Pediatric Cardiology.

[99]  B. Maron.  Contemporary Reviews in Cardiovascular Medicine Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy , 2010 .

[100]  D. Pennell,et al.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. , 2003, European heart journal.

[101]  S. Ommen,et al.  Myths about surgical myectomy: rumors of its death have been greatly exaggerated. , 2008, The American journal of cardiology.

[102]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[103]  O. Schober,et al.  Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. , 1999, European heart journal.

[104]  A. Tajik,et al.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[105]  C. Robertson,et al.  Extreme tachycardia complicating the use of disopyramide in atrial flutter. , 1980, British heart journal.

[106]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[107]  N. Krasnow,et al.  Reversible obstruction of the ventricular outflow tract. , 1963, The American journal of cardiology.

[108]  M. Frenneaux,et al.  Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. , 1990, Circulation.

[109]  I. Palacios,et al.  Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. , 2006, European Heart Journal.

[110]  J. Ross,et al.  Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[111]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[112]  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2002 .

[113]  U. Gleichmann,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. , 1998, Circulation.

[114]  K. Bailey,et al.  Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. , 1995, Circulation.

[115]  J. Bouret,et al.  [Obstructive myocardiopathy and pregnancy]. , 1993, Journal de gynecologie, obstetrique et biologie de la reproduction.

[116]  Michael V. Green,et al.  Effects of Verapamil on Left Ventricular Systolic Function and Diastolic Filling in Patients with Hypertrophic Cardiomyopathy , 1981, Circulation.

[117]  B. Maron,et al.  Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. , 2005, Heart rhythm.

[118]  B. Maron.  Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. , 2007, Circulation.

[119]  B. Maron,et al.  Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. , 1995, Journal of the American College of Cardiology.

[120]  B. Maron,et al.  Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. , 1995, Circulation.

[121]  S. Epstein,et al.  Prognostic Determinants in Hypertrophic Cardiomyopathy: Prospective Evaluation of a Therapeutic Strategy Based on Clinical, Holter, Hemodynamic, and Electrophysiological Findings , 1992, Circulation.

[122]  M. Chiariello,et al.  Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[123]  E. Braunwald,et al.  Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. , 1962, The American journal of cardiology.

[124]  C. Semsarian,et al.  Sudden cardiac death in familial hypertrophic cardiomyopathy: Are “benign” mutations really benign? , 1997, Pathology.

[125]  B. Maron,et al.  Long-term clinical consequences of intense, uninterrupted endurance training in olympic athletes. , 2010, Journal of the American College of Cardiology.

[126]  S. Nagueh,et al.  Regression of Left Ventricular Hypertrophy After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy , 2001, Circulation.

[127]  W. Mckenna,et al.  Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. , 1997, Circulation.

[128]  D Tripodi,et al.  Long‐term Results of Dual‐Chamber (DDD) Pacing in Obstructive Hypertrophic Cardiomyopathy: Evidence for Progressive Symptomatic and Hemodynamic Improvement and Reduction of Left Ventricular Hypertrophy , 1994, Circulation.

[129]  Lukas Kappenberger,et al.  Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy , 1992, The Lancet.

[130]  J. Belmont,et al.  Clinical Spectrum, Morbidity, and Mortality in 113 Pediatric Patients With Mitochondrial Disease , 2004, Pediatrics.

[131]  W. Roberts,et al.  Anomalous Insertion of Papillary Muscle Directly Into Anterior Mitral Leaflet in Hypertrophic Cardiomyopathy: Significance in Producing Left Ventricular Outflow Obstruction , 1991, Circulation.

[132]  Ana Morales,et al.  Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2009, Circulation. Heart failure.

[133]  E. W. Hancock,et al.  Muscular Subaortic Stenosis: Prevention of Outflow Obstruction with Propranolol , 1968, Circulation.

[134]  M. Gold,et al.  Sustained Ventricular Tachycardia Following Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy , 2005, Pacing and clinical electrophysiology : PACE.

[135]  P. Dimitrow,et al.  Echocardiographic risk factors predisposing to sudden cardiac death in hypertrophic cardiomyopathy , 2004, Heart.

[136]  H. Kuhn,et al.  Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. , 1999, European heart journal.

[137]  B. Maron,et al.  Morphologic determinants of hemodynamic state after ventricular septal myotomy-myectomy in patients with obstructive hypertrophic cardiomyopathy: M mode and two-dimensional echocardiographic assessment. , 1984, Circulation.

[138]  W. Mckenna,et al.  Amiodarone dose titration: a method to minimise side effects during long term therapy. , 1986, British journal of clinical practice. Supplement.

[139]  C. Autore,et al.  Prognosis of Asymptomatic Patients With Hypertrophic Cardiomyopathy and Nonsustained Ventricular Tachycardia , 1994, Circulation.

[140]  B. Gersh,et al.  How should hypertrophic cardiomyopathy be classified?: What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. , 2009, Circulation. Cardiovascular genetics.

[141]  R. Bonow,et al.  Regional left ventricular asynchrony and impaired global left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. , 1987, Journal of the American College of Cardiology.

[142]  W. Williams,et al.  Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy , 2005, Circulation.

[143]  C. Pollick.  Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. , 1982, The New England journal of medicine.

[144]  B. Bembi,et al.  Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II , 2006, Human mutation.

[145]  F. T. ten Cate,et al.  Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. , 2009, European heart journal.

[146]  Maurizio Schiavon,et al.  Does sports activity enhance the risk of sudden death in adolescents and young adults? , 2003, Journal of the American College of Cardiology.

[147]  B. Maron,et al.  Current operative treatment of obstructive hypertrophic cardiomyopathy. , 1988, Circulation.

[148]  A. Tajik,et al.  Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. , 2002, Journal of the American College of Cardiology.

[149]  S. Solomon,et al.  Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic Cardiomyopathy , 2002, Circulation.

[150]  J. Hodges,et al.  Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. , 2009, Heart rhythm.

[151]  N. Smedira,et al.  Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. , 2010, Journal of the American College of Cardiology.

[152]  S. Larson,et al.  Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. , 1987, Circulation.

[153]  L. Faber,et al.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients , 2000, Heart.

[154]  A. Tajik,et al.  Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[155]  B. Maron,et al.  Hypertrophic Cardiomyopathy Prognostic Value of Systemic Blood Pressure Response During Exercise in a Community-Based Patient Population With Hypertrophic Cardiomyopathy , 2016 .

[156]  S. Lipshultz,et al.  Clinical approach to genetic cardiomyopathy in children. , 1996, Circulation.

[157]  N. Lakkis.  New treatment methods for patients with hypertrophic obstructive cardiomyopathy , 2000, Current opinion in cardiology.

[158]  W. Manning,et al.  Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2008, The American journal of cardiology.

[159]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[160]  W. Mckenna,et al.  Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. , 1997, European heart journal.

[161]  B. Maron,et al.  Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. , 1992, Journal of the American College of Cardiology.

[162]  D. Kass,et al.  Diastolic Compliance of Hypertrophied Ventricle Is Not Acutely Altered by Pharmacologic Agents Influencing Active Processes , 1993, Annals of Internal Medicine.

[163]  B. Maron,et al.  Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. , 2010, European heart journal.

[164]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy with survival to advanced age. , 2003, Journal of the American College of Cardiology.

[165]  A. Kadish,et al.  Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients. , 2008, Heart rhythm.

[166]  I. Palacios,et al.  Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. , 2006, The American journal of cardiology.

[167]  R. Bonow,et al.  Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. , 1989, Circulation.

[168]  B. Maron,et al.  Novel hypertrophic cardiomyopathy phenotype: segmental hypertrophy isolated to the posterobasal left ventricular free wall. , 2010, The American journal of cardiology.

[169]  F. Flachskampf,et al.  Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. , 1995, Circulation.

[170]  B. Maron,et al.  Prevalence and Clinical Significance of Aortic Root Dilation in Highly Trained Competitive Athletes , 2010, Circulation.

[171]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[172]  B. Maron,et al.  From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy , 2003, Heart.

[173]  A. Dipchand,et al.  Outcomes of pediatric patients with hypertrophic cardiomyopathy listed for transplant. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[174]  Z. Kornacewicz-Jach,et al.  Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy , 1998, Heart.

[175]  F. T. ten Cate,et al.  Permanent pacing for complete atrioventricular block after nonsurgical (alcohol) septal reduction in patients with obstructive hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[176]  E. Brockenbrough,et al.  Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. , 1961, Annals of surgery.

[177]  F O Mueller,et al.  Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. , 1996, JAMA.

[178]  E D Wigle,et al.  Mutations of the β myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis , 2003, Heart.

[179]  N. Lakkis,et al.  Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. , 2009, European heart journal.

[180]  F. Cuoco.  Role of Family History of Sudden Death in Risk Stratification and Prevention of Sudden Death With Implantable Defibrillators in Hypertrophic Cardiomyopathy , 2011 .

[181]  G. Giannakoulas,et al.  Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. , 2009, The American journal of cardiology.

[182]  B. Maron,et al.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[183]  J. Seidman,et al.  Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. , 1992, The Journal of clinical investigation.

[184]  P. Elliott,et al.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.

[185]  A. Tajik,et al.  Dual chamber pacing for patients with hypertrophic obstructive cardiomyopathy: a clinical perspective in 2000. , 2000, Mayo Clinic proceedings.

[186]  A. Tajik,et al.  Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[187]  D. Fassbender,et al.  Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. , 2004, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[188]  H Niimura,et al.  Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. , 2001, Journal of the American College of Cardiology.

[189]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[190]  B. Maron,et al.  Determinants for clinical diagnosis of hypertrophic cardiomyopathy. , 2006, American Journal of Cardiology.

[191]  J. Veselka,et al.  Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective , 2009, Heart and Vessels.

[192]  D. Fassbender,et al.  Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. , 2007, International journal of cardiology.

[193]  E. Behr,et al.  Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death , 2002, Heart.

[194]  D. Atsma,et al.  The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening. , 2010, European heart journal.

[195]  R. Kwong,et al.  Clinical application of cardiac CMR. , 2009, Reviews in cardiovascular medicine.

[196]  D. Holmes,et al.  Clinical practice. Hypertrophic obstructive cardiomyopathy. , 2004, The New England journal of medicine.

[197]  G. Danielson,et al.  Hypertrophic obstructive cardiomyopathy in pediatric patients: results of surgical treatment. , 1996, The Journal of thoracic and cardiovascular surgery.

[198]  J. Seidman,et al.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy. , 2005, The New England journal of medicine.

[199]  K. Borisov,et al.  Management of Symptomatic Hypertrophic Obstructive Cardiomyopathy - Long-Term Results after Surgical Therapy , 1999, The Thoracic and cardiovascular surgeon.

[200]  S. Themistoclakis,et al.  Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. , 2006, Heart rhythm.

[201]  Michael J Ackerman,et al.  Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy , 2007, Nature Genetics.

[202]  M. Chiariello,et al.  Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. , 1996, The American journal of cardiology.

[203]  M A Proschan,et al.  Echocardiographic Assessment of Mitral Valve Size in Obstructive Hypertrophic Cardiomyopathy Anatomic Validation From Mitral Valve Specimen , 1993, Circulation.

[204]  B. Maron,et al.  Distinguishing hypertrophic cardiomyopathy from athlete’s heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening , 2009, British Journal of Sports Medicine.

[205]  S. Ommen,et al.  Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. , 2008, The American journal of cardiology.

[206]  B. Maron,et al.  Hypertrophic cardiomyopathy: a discussion of nomenclature. , 1979, The American journal of cardiology.

[207]  M. Frenneaux,et al.  Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. , 1990, Journal of the American College of Cardiology.

[208]  U. Gleichmann,et al.  Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: Detection of threatening myocardial necrosis distant from the septal target area , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[209]  W. Roberts,et al.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. , 1986, Journal of the American College of Cardiology.

[210]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[211]  G. Bonsel,et al.  Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: A cross‐sectional cohort study , 2009, American journal of medical genetics. Part A.

[212]  Michael J Ackerman,et al.  Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. , 2006, Mayo Clinic proceedings.

[213]  Michael V. Green,et al.  Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe. , 1983, Circulation.

[214]  S. Nagueh,et al.  A prospective follow‐up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy—The baylor experience (1996–2002) , 2005, Clinical cardiology.

[215]  W. Chan,et al.  A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[216]  D. Pennell,et al.  Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography , 2004, Heart.

[217]  R. Siegel,et al.  Obstruction is unimportant in the pathophysiology of hypertrophic cardiomyopathy. , 1986, Postgraduate medical journal.

[218]  Heidi L Rehm,et al.  Shared genetic causes of cardiac hypertrophy in children and adults. , 2008, The New England journal of medicine.

[219]  M. Götte,et al.  Early Onset and Progression of Left Ventricular Remodeling After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy , 2005, Circulation.

[220]  R. Brock.  Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis. , 1957, Guy's Hospital reports.

[221]  M. Quiñones,et al.  Acute Effect of Nonsurgical Septal Reduction Therapy on Regional Left Ventricular Asynchrony in Patients With Hypertrophic Obstructive Cardiomyopathy , 2002, Circulation.

[222]  W. Roberts,et al.  Diversity of Structural Mitral Valve Alterations in Hypertrophic Cardiomyopathy , 1992, Circulation.

[223]  H. Schaff,et al.  Results of operation for hypertrophic obstructive cardiomyopathy in children and adults less than 40 years of age. , 1989, Circulation.

[224]  J. Goodwin,et al.  Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. , 1982, British heart journal.

[225]  A. Tajik,et al.  Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[226]  V. Dilsizian,et al.  Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[227]  P. Elliott,et al.  Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. , 2006, European heart journal.

[228]  B. Maron,et al.  Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. , 2004, The Journal of thoracic and cardiovascular surgery.

[229]  R. Falicov,et al.  Mid-ventricular obstruction: a variant of obstructive cardiomyopathy. , 1976, The American journal of cardiology.

[230]  I. Olivotto,et al.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[231]  C. Semsarian,et al.  Multiple Mutations in Genetic Cardiovascular Disease: A Marker of Disease Severity? , 2009, Circulation. Cardiovascular genetics.

[232]  Michael V. Green,et al.  Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. , 1985, Circulation.

[233]  The "duty to warn" a patient's family members about hereditary disease risks. , 2005, JAMA.

[234]  E. Braunwald,et al.  Studies on Digitalis: V. Comparison of the Effects of Ouabain on Left Ventricular Dynamics in Valvular Aortic Stenosis and Hypertrophic Subaortic Stenosis , 1962, Circulation.

[235]  W. Mckenna,et al.  Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. , 1981, The American journal of cardiology.

[236]  A. Tajik,et al.  Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[237]  H. Sugihara,et al.  Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy , 1998, Annals of nuclear medicine.

[238]  B. McCrindle,et al.  Myocardial bridging in children with hypertrophic cardiomyopathy--a risk factor for sudden death. , 1998, The New England journal of medicine.

[239]  W. Williams,et al.  Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. , 2000, Journal of the American College of Cardiology.

[240]  W. Roberts,et al.  Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. , 1983, Circulation.

[241]  L. Rydén,et al.  Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. , 1999, The American journal of cardiology.

[242]  B. Maron,et al.  Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. , 1999, Journal of the American College of Cardiology.

[243]  Y. Doi,et al.  Hypertrophic cardiomyopathy in the elderly: significance of atrial fibrillation. , 2001, Journal of cardiology.

[244]  B. Maron,et al.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. , 1979, Circulation.

[245]  M. Link,et al.  Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction , 2008 .

[246]  N. Smedira,et al.  Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. , 2008, The Annals of thoracic surgery.

[247]  E. Braunwald,et al.  STUDIES ON DIGITALIS. IV. OBSERVATIONS IN MAN ON THE EFFECTS OF DIGITALIS PREPARATIONS ON THE CONTRACTILITY OF THE NON-FAILING HEART AND ON TOTAL VASCULAR RESISTANCE. , 1961, The Journal of clinical investigation.

[248]  Michel Haissaguerre,et al.  Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[249]  P. Serruys,et al.  Long-Term Outcome of Alcohol Septal Ablation in Patients With Obstructive Hypertrophic Cardiomyopathy: A Word of Caution , 2010, Circulation. Heart failure.

[250]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[251]  E. Aliot,et al.  Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. PIC study group. Pacing In Cardiomyopathy. , 1999, European heart journal.

[252]  D. Holmes,et al.  Alcohol septal ablation for hypertrophic cardiomyopathy: Indications and technique , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[253]  S. Ommen,et al.  Dynamic left ventricular outflow tract obstruction in acute coronary syndromes: an important cause of new systolic murmur and cardiogenic shock. , 2000, Mayo Clinic proceedings.

[254]  L. Rydén,et al.  Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest. , 1997, European heart journal.

[255]  R. Robbins,et al.  Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. , 1996, The Journal of thoracic and cardiovascular surgery.

[256]  Y. Birnbaum,et al.  Monomorphic ventricular tachycardia: a late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy. , 2004, The American journal of the medical sciences.

[257]  W. Roberts,et al.  Causes of sudden death in competitive athletes. , 1986, Journal of the American College of Cardiology.

[258]  A. van Rossum,et al.  Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. , 2004, Journal of the American College of Cardiology.

[259]  A. Tajik,et al.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[260]  P. Phongsavan,et al.  Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy , 2008, Genetics in Medicine.

[261]  D. E. Cobb,et al.  Idiopathic Hypertrophic Subaortic Stenosis: III. Intraoperative Studies of the Mechanism of Obstruction and Its Hemodynamic Consequences , 1964 .

[262]  W. Stevenson,et al.  Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. , 2001, JAMA.

[263]  Heiko Mahrholdt,et al.  Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[264]  J. Towbin,et al.  Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. , 2005, Journal of the American College of Cardiology.

[265]  S. Michie,et al.  Information recall in genetic counselling: a pilot study of its assessment. , 1997, Patient education and counseling.

[266]  J. Seidman,et al.  The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.

[267]  B. Maron,et al.  Pilots, hypertrophic cardiomyopathy, and issues of aviation and public safety. , 2004, The American journal of cardiology.

[268]  C. Autore,et al.  Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy , 2009, Circulation.

[269]  Seung‐Jung Park,et al.  Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy , 1999 .

[270]  D TEARE,et al.  ASYMMETRICAL HYPERTROPHY OF THE HEART IN YOUNG ADULTS , 1958, British heart journal.

[271]  B. Gersh,et al.  The case for surgery in obstructive hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[272]  T. Imaizumi,et al.  Predictors of sudden cardiac death in hypertrophic cardiomyopathy. , 1998, The American journal of cardiology.

[273]  Christine E Seidman,et al.  The genetic basis for cardiac remodeling. , 2005, Annual review of genomics and human genetics.

[274]  S. Mennel,et al.  Ventricular Tachycardia Complicating Alcohol Septal Ablation , 2004 .

[275]  P. Poole‐Wilson,et al.  Cardiovascular Magnetic Resonance in Cardiac Amyloidosis , 2005, Circulation.

[276]  M. Sherrid,et al.  Resection-plication-release for hypertrophic cardiomyopathy: clinical and echocardiographic follow-up. , 2008, The Annals of thoracic surgery.

[277]  B. Maron,et al.  Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. , 1998, Circulation.

[278]  J. Stockman.  Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children: Findings From the Pediatric Cardiomyopathy Registry , 2009 .

[279]  S. Ommen,et al.  Septal reduction therapy for obstructive hypertrophic cardiomyopathy and sudden death: what statistics cannot tell you. , 2010, Circulation. Cardiovascular interventions.

[280]  M. Laakso,et al.  Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes. , 2006, American heart journal.

[281]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[282]  D Tripodi,et al.  Results of permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy. , 1994, The American journal of cardiology.

[283]  B. Gersh,et al.  Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2008, Circulation.

[284]  T. Meitinger,et al.  A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated β-myosin heavy chain genes , 1998, Human Genetics.

[285]  M. Vannan,et al.  Myocardial mechanics explains the time course of benefit for septal ethanol ablation for hypertrophic cardiomyopathy. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[286]  M. Sherrid,et al.  Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. , 1988, The American journal of cardiology.

[287]  Bruce D Gelb,et al.  Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. , 2006, Human molecular genetics.

[288]  G. Bonsel,et al.  Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: The patients' perspective , 2009, American journal of medical genetics. Part A.

[289]  G. Jensen,et al.  Circulatory effects of intravenous disopyramide in heart failure. , 1976, The Journal of international medical research.

[290]  A. Waldo.  Substrate and Procedural Predictors of Outcomes After Catheter Ablation for Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy , 2009 .

[291]  A. Tajik,et al.  Adverse Prognosis of Patients With Hypertrophic Cardiomyopathy Who Have Epicardial Coronary Artery Disease , 2003, Circulation.

[292]  B. Maron,et al.  Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[293]  D. Simel,et al.  Meta-Analyses of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy: Comparative Rates of Overall Mortality and Sudden Cardiac Death After Treatment , 2010, Circulation. Cardiovascular interventions.

[294]  M. Sheppard,et al.  Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance , 2010 .

[295]  B. Gersh,et al.  Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy , 2009, Heart.

[296]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[297]  M. Link,et al.  Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. , 2009, Heart rhythm.

[298]  U. Sigwart.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.

[299]  R L Popp,et al.  Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. , 1988, Journal of the American College of Cardiology.

[300]  F. Gaita,et al.  Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. , 2007, The American journal of cardiology.

[301]  B. Maron.  Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[302]  I. Palacios,et al.  Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy , 2006, Heart.

[303]  J. Yagüe,et al.  Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[304]  I. Palacios,et al.  Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. , 2006, The American journal of cardiology.

[305]  A. Tajik,et al.  Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future , 2007, Heart.

[306]  W. Williams,et al.  Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. , 2005, The Journal of thoracic and cardiovascular surgery.

[307]  B. Maron,et al.  Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. , 1989, Journal of the American College of Cardiology.

[308]  S. Nagueh,et al.  Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[309]  S. Ernst,et al.  Complete pulmonary vein isolation guided by three-dimensional electroanatomical mapping for the treatment of paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. , 2005, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[310]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[311]  I. Palacios,et al.  Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. , 2009, The American journal of cardiology.

[312]  J. Seidman,et al.  Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. , 1991, The New England journal of medicine.

[313]  A. Tajik,et al.  Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. , 2007, European heart journal.

[314]  J. Towbin,et al.  Diagnostic, Prognostic and Therapeutic Implications of Genetic Testing for Hypertrophic Cardiomyopathy , 2010 .

[315]  B. Maron,et al.  Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. , 2008, Journal of the American College of Cardiology.

[316]  S. Colan,et al.  Factors Associated With Establishing a Causal Diagnosis for Children With Cardiomyopathy , 2006, Pediatrics.

[317]  P. Serruys,et al.  Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. , 2008, The American journal of cardiology.

[318]  S. Ommen,et al.  Septal myectomy after previous septal artery ablation in hypertrophic cardiomyopathy. , 2007, Mayo Clinic proceedings.

[319]  S. Ommen,et al.  Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? , 2007, Journal of the American College of Cardiology.

[320]  Barry J Maron,et al.  The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. , 2006, Circulation.

[321]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[322]  A. Tajik,et al.  Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. , 2004, Journal of the American College of Cardiology.

[323]  M. Josephson,et al.  Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). , 1999, Circulation.

[324]  A. Tajik,et al.  Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. , 1996, Circulation.

[325]  B. Maron,et al.  Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. , 2011, The American journal of cardiology.

[326]  J. Towbin,et al.  Danon Disease as an Underrecognized Cause of Hypertrophic Cardiomyopathy in Children , 2005, Circulation.

[327]  C. Stellbrink,et al.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience , 2008, Clinical Research in Cardiology.

[328]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[329]  W. Williams,et al.  Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. , 1992, Journal of the American College of Cardiology.

[330]  J. Wodniecki,et al.  Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. , 1993, Cardiology.

[331]  S. Michie,et al.  Objectives of genetic counselling: differing views of purchasers, providers and users. , 1998, Journal of Public Health Medicine.

[332]  K. P. Carney,et al.  Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[333]  C. Semsarian,et al.  Long-term follow-up of patients with obstructive hypertrophic cardiomyopathy treated with dual-chamber pacing. , 2005, The American journal of cardiology.

[334]  A. Ralph-Edwards,et al.  Hypertrophic cardiomyopathy: current understanding and treatment objectives , 2008, Journal of Clinical Pathology.

[335]  M. Verani,et al.  Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. , 1998, Circulation.

[336]  Jeroen J. Bax,et al.  Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies. , 2008, JACC. Cardiovascular imaging.

[337]  J. Seidman,et al.  Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics , 2007, Journal of cardiovascular electrophysiology.

[338]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[339]  I. Komuro,et al.  Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy. , 2007, International journal of cardiology.

[340]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[341]  W. Manning,et al.  Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. , 2009, Journal of the American College of Cardiology.

[342]  A. Tajik,et al.  Myocardial bridging in adult patients with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[343]  M. Verani,et al.  Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. , 1998, Journal of the American College of Cardiology.

[344]  E. W. Hancock,et al.  Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. , 1973, The American journal of cardiology.

[345]  J. Dussaule,et al.  Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. , 1985, American heart journal.

[346]  G. Vlahakes,et al.  Management of Symptoms in Hypertrophic Cardiomyopathy , 2008, Circulation.

[347]  B. Maron,et al.  Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. , 1981, The American journal of cardiology.

[348]  W. Williams,et al.  Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. , 1985, Progress in cardiovascular diseases.

[349]  N. Smedira,et al.  Abnormally thickened papillary muscle resulting in dynamic left ventricular outflow tract obstruction: an unusual presentation of hypertrophic cardiomyopathy. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[350]  J. Veselka,et al.  Age-related hemodynamic and morphologic differences in patients undergoing alcohol septal ablation for hypertrophic obstructive cardiomyopathy. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[351]  Deborah H. Kwon,et al.  Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. , 2008, JACC. Cardiovascular interventions.

[352]  E. Wigle,et al.  Medical and Surgical Treatment of the Cardiomyopathies , 1974, Circulation research.

[353]  Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. , 2003, Journal of the American College of Cardiology.

[354]  ThomasKleemann,et al.  Annual Rate of Transvenous Defibrillation Lead Defects in Implantable Cardioverter-Defibrillators Over a Period of >10 Years , 2007 .

[355]  S. Antonarakis,et al.  A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy , 2008, Human mutation.

[356]  Andrew S. Mugglin,et al.  Longevity of Sprint Fidelis Implantable Cardioverter-Defibrillator Leads and Risk Factors for Failure: Implications for Patient Management , 2011, Circulation.

[357]  A. Camm,et al.  DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. , 1996, Heart.

[358]  E. Benjamin,et al.  ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiova , 2009, Journal of the American College of Cardiology.

[359]  L. Hougs,et al.  Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives , 2009, Human mutation.

[360]  M. S. Hamid,et al.  Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. , 2002, European heart journal.

[361]  H. Kuhn,et al.  Transcoronary Ablation of Septal Hypertrophy Does Not Alter ICD Intervention Rates in High Risk Patients with Hypertrophic Obstructive Cardiomyopathy , 2005, Pacing and clinical electrophysiology : PACE.